Good morning, and thank you for participating. At this time, all participants are in listen-only mode. Later, we will conduct a question-and-answer session. As a reminder, this conference call will be recorded. I would now like to turn the call over to Cameron Radanovic of EVC Group. Mr. Radanovic, please go ahead. Thank you, Operator. Good morning, and welcome to the LENSAR Q3 2024 financial results conference call. Earlier this morning, the company issued a press release providing an overview of its financial results for the quarter ended September 30, 2024. This press release is available on the Investor Relations section of the company's website at www.lensar.com. Joining me on the call today is Nick Curtis, Chief Executive Officer, who will review the company's recent business and operational progress. Following his comments, Tom Staab, Chief Financial Officer, will provide an overview of the company's financial highlights before turning the call back over to the Operator to facilitate answering any questions you may have. Today's conference call will contain certain forward-looking statements, including those statements regarding future results, unaudited, and forward-looking financial information, as well as the company's future performance and/or achievements. These statements are subject to known and unknown risks and uncertainties, which may cause the company's actual results, performance, or achievements to be materially different from any future results or performance expressed or implied in this presentation. You should not place undue reliance on these forward-looking statements. For additional information, including a detailed discussion of the company's risk factors, please refer to the company's documents filed with the Securities and Exchange Commission, which can be accessed on the website. In addition, this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, November 7, 2024. LENSAR undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this live call. With that, it's my pleasure to turn the call over to Nick Curtis. Nick? Thank you, Cam, and good morning to everyone. I appreciate you joining us, and I'm excited to report that LENSAR hit another record-breaking Q3. Starting from an ALLY system placement standpoint, the Q3 was fueled by the recent market expansion to the EU and Taiwan as we placed a total of 24 new ALLY systems, an outstanding 118% increase over what had been a strong Q3 of 2023 and a 41% increase over the Q2 of 2024. This was driven in part by very solid performance outside of the United States, where we sold 11 ALLY systems following mid-Q3 regulatory clearances in Europe, Switzerland, and Taiwan. The rapid trajectory and success of the ALLY international launch speaks to several key factors. First, the advanced planning and collaboration between our commercial team and distributor partners in training, field service, and clinical applications, as well as our on-site assistance with first installs allowed for a rapid response after clearance to ship ALLY systems. Second, we properly prepared the market, building interest by supporting our partners in attending multiple conferences, meeting with surgeons and performing demos, shared learnings from U.S. launch, and clinic experience. Third, worked with our distributor partners on two of the larger PE groups in securing ALLY system commitments. Fourth, facilitated U.S. KOL surgeons using ALLY to network and perform presentations in several of the conference venues. And last, I was fortunate enough to have participated in several panel discussions just prior to receiving clearance and shortly thereafter: the ACOS European meeting in Prague and recently the ESCRS in Barcelona. I'd like to recognize and thank our distributor partners for their close collaboration and commitment in making the initial ALLY launch so successful. The strong global interest in ALLY is creating a healthy expansion of new to LENSAR customer sites, which will result in the continued growth of our recurring revenues. Our total installed base of ALLY systems grew to over 100 on a global basis, reflecting a 170% increase from September 30 of last year. LENSAR's overall installed base, including the legacy LENSAR laser systems, has grown to 355 systems, representing a 20% increase over Q3 2023 and an 8% increase quarter over quarter. In addition to our strong placement activity, we continue to build our pipeline of executed contracts and pending installations. We finished the quarter with a backlog of 24 systems, which we expect to install over the next six months. I think it would be beneficial at this juncture to provide you with a little bit of color around backlog, the time from contract to installation, training, and revenue recognition in the U.S. and internationally. In the U.S., on average, it takes approximately 50 days from the time of reaching a signed agreement to installation and first surgeon trained. We schedule and perform a site and surgical visit in advance of shipping the ALLY in order to determine the right placement and specifications to install ALLY, educate us on their current process and flow, their surgeons' and site preferences in performing their cataract surgery, as well as what a typical surgical day entails. Then we schedule a convenient ship date, provide initial online training, as well as an outline on what to expect after installation. On-site training of staff, as well as the surgeon, is followed by live surgery. We allocate three surgical days with each surgeon, performing a minimum of five cases each day, utilizing all the features of ALLY to certify the staff and surgeon. At this time, we recognize a revenue on the system. Only then, all personnel that work with the device need to be certified for use. All surgeons must perform a minimum of 15 cases. If a system has fully executed contract but is not installed in the quarter the agreement is signed, it becomes a backlog system. This backlog is dependent on the steps I just described, as well as any unique installation requirements, such as an electrical modification, or the room is under construction, or they have a competitive system to be removed or waiting for a contract expiration, etc. The backlog could take some time, and despite the customer commitment, remains in a state of flow. Outside the U.S., revenue recognition for LENSAR is very different. Outside the U.S., our distributor partners are responsible for the installation and training. However, when the ALLY leaves LENSAR's dock, the system becomes the property of the distributor, and we recognize the system revenue. However, it still takes approximately 60-90 days after installation for the site and surgeon to begin to get to a normalized run rate. In the bigger picture, it is important to understand the process and thus why there is a rolling or staggered effect on procedure growth and revenue recognition over time. This is a primary driver as to why our quarterly placements can be lumpy and uneven. Timing with the number of activities can be dependent on many factors. Again, excuse me, previously we discussed a large PE Group deal that had been executed just after the close of a quarter. This is a game of inches, and we're gaining each quarter in the important areas of increasing recurring revenues through procedures and market share gains and footprint. We achieved $13.5 million of revenue in the Q3, an increase of over 38% from the Q3 of last year, which, as I just described, was attributable to robust growth in system placements, including 11 OUS system sales. Turning to procedures, we had another quarter of strong growth, with procedure volumes increasing 29% over the Q3 of 2023 and U.S. procedures increasing 22% year- over- year. We expect this trend to continue moving forward as utilization on newly placed systems ramps up, particularly with users who are new to LENSAR having converted to ALLY from older competing lasers. On average, we see approximately a 13% increase on a LENSAR LLS moving to ALLY, and the new to LENSAR ALLYs are net 100% new recurring revenue procedures from the start. The more systems we install, the more procedure revenue will begin to grow. We're really focused on expanding our footprint in placements by first converting competitive systems, followed by transitioning current LENSAR LLS users to ALLY. Third is adding second or multiple systems with high volume, high conversion rate sites and surgeons, as well as additional site expansions. And finally, what we refer to as cataract laser naive accounts, which continue to grow the overall entire market. According to a recent Market Scope estimate, our share of the U.S. procedure market increased to approximately 20% as of September 30. This is a really healthy increase of 1.5% over the Q2. But more impressively, we have gained 3.5% market share in the past year and nearly 6% since launching ALLY in the summer of 2022. The U.S. is the largest premium cataract market in the world, and even though we're competing directly against the largest ophthalmology companies in the world, we have succeeded in achieving significant market share growth and securing 20% of the U.S. procedure market. At LENSAR, we're incredibly proud of this achievement. And most importantly, it demonstrates U.S. surgeons' recognition of the technology advancement in providing better patient outcomes, increased efficiencies in throughput and flow, and financial efficiencies the ALLY system provides over the aging competitive lasers from our much larger competitors. With recent approvals, we can strive to add market share outside the United States as we continue to receive ALLY clearance in additional countries. Procedure volumes directly correlate to our recurring revenue rate, which we believe is a highly effective, very important measure of our growth and longer-term success. In the Q3, our recurring revenue totaled approximately $9.9 million, with $38 million in recurring revenue on a trailing 12-month basis through the Q3 of 2024. This is an increase of 22% over the 12 months ended September 30, 2023. And with more than 40 systems placed in the last two quarters alone, we expect recurring revenue to grow in a material way on a rolling forward basis as each of these systems passes 90 days from install date and activity continues to ramp on these newly installed lasers. As I mentioned, we attended several U.S. and OUS congresses, including the ESCRS and AAO, where we performed over 100 ALLY demonstrations and booth meetings that have resulted in a significant number of new prospects for our U.S. sales team, as well as our partner distributors in the EU and Southeast Asia. Differentiating ALLY but demonstrating the robotic intelligence, precision, and reproducibility, as well as the significantly enhanced efficiencies and workflow, are driving the interest. And as they say, a picture says a thousand words. And when they see it, the potential benefits become obvious. To that end, I'm incredibly proud of what the LENSAR team has accomplished this quarter and through the first nine months of 2024. We successfully launched ALLY in the EU and Taiwan with an overwhelmingly positive response. This is a testament to the transformative power of ALLY and its potential to positively impact the future of robotic cataract surgery. We're starting to benefit from the universal appeal on a broader scale with ALLY now available in multiple geographies outside the United States. As we look ahead, LENSAR is incredibly well positioned heading into the Q4, which is traditionally our strongest period of the year, and we're setting the stage effectively for continued success in 2025 and beyond. We're very excited about the potential of our pipeline and the ability to further innovate and revolutionize the field of robotic cataract laser surgery. Now let me turn the call over to Tom to cover our financial highlights for the quarter. Tom? Thank you, Nick. Just a few remarks from me on our extremely strong Q3 performance. Revenue was $13.5 million in the Q3 of 2024 compared to $9.8 million in the Q3 of 2023, representing an exceptional 38% increase. While we experienced growth across all revenue line items, the strong quarter can be largely attributed to the 11 systems sold outside the United States following regulatory approvals in the European Union and Taiwan. These clearances represented a huge milestone for us, opening operating regions outside the United States and allowing us to fill a backlog that had accumulated over the last two years. We expected pent-up demand for ALLY in these regions, but we were a little surprised with the sheer system sales volume given the mid-quarter clearances. Distributor and underlying surgeon demand exceeded our internal expectations. Looking forward, we expect the Q4 ALLY demand outside the United States to approximate the 10 to 11 lasers we sold in the Q3. Another interesting aspect of our results was our trailing 12-month recurring revenue of $38 million, as Nick mentioned in his remarks. This represented a 22% increase over the trailing 12-month activity in 2023. Thus, we are growing our recurring revenue at a 20% plus clip rate, with this growth to date entirely associated with the U.S. marketplace, as it is too early to see any influence from the recent EU and Taiwan installations. A few other noteworthy aspects of the quarter: we have installed 38 ALLY systems since June 1, representing an approximate 75% of our total 2024 ALLY placements. Many of these systems have yet to reach optimal steady-state procedure volume due to surgeon summer vacation schedules, the extended timing associated with training multiple surgeons, practice and ASC integration, and just normal transition time for surgeons to achieve their optimal procedure run rate. Accordingly, we expect procedure volume and growth to be even stronger in the Q4. Lastly, 79% of our 2024 U.S. placements have been with new to LENSAR customers. We consider this metric very important as, one, it supports the continual and substantial growth we see in our U.S. procedure market share, especially when these customers reach a steady procedure run rate, and two, it further validates the benefits of ALLY as seen in the surgeon's eyes. In summary, we expect these recent ALLY placements to begin to contribute significantly throughout the Q4 and our recurring revenue growth to steepen when the recently installed U.S., EU, and Taiwan lasers reach their optimal run rate. The benefits of these placements are expected to begin in the Q4 and continue into 2025. Gross margin for the quarter was $6.3 million, representing a gross margin percentage of 46% compared to $4.9 million and 50% gross margin realized in the Q4 of 2023. We continue to expect a gross margin percentage of approximately 50% for this fiscal year. Our year-to-date gross margin percentage currently sits at 51%, but we expect a higher mix of system sales to pull this percentage down slightly in the Q4. The Q4 is generally the strongest quarter from a seasonal perspective, and due to the timing of system placements, I would expect a healthy year-over-year procedure volume increase in the Q4. Total operating expenses for the Q4 of 2024 were $7.5 million compared to $6.9 million in the Q4 of 2023. The increase in operating expenses was primarily attributable to higher SG&A spend, partially offset by lower R&D expenses. Net loss for the quarter was $1.5 million, or a $0.13 loss per common share, compared to $2.6 million net income, or a $0.13 gain per common share in the Q4 of 2023. The income in Q3 2023 was due to a $4.7 million favorable swing in our warrant valuation, which took us from an operating loss to net income in that quarter. To evaluate our results and operations more naturally, let us look at our adjusted EBITDA results. We were pleased that we achieved a positive Adjusted EBITDA of $429,000 as compared to a negative $1.4 million Adjusted EBITDA in the Q4 of last year, representing a favorable $1.8 million swing. As of September 30, 2024, we had cash and cash equivalents of $18.6 million as compared to $24.6 million at December 31, 2023, and $15.4 million at June 30, 2024. As all non-U.S. ALLY placements are sales, our cash increased $3.1 million in the Q4, largely due to filling the EU and Taiwan backlog. Going forward, we will continue to maintain an appropriate inventory level to respond to global ALLY demand, and we will also strategically expand our ALLY fleet of lease systems in the United States to further increase U.S. procedure market share and our recurring revenue foundation. Now I'd like to turn the call over to the operator, and we look forward to answering your questions. Operator? At this time, I would like to remind everyone, in order to ask questions, press star, then the number one on your telephone keypad. Your first question comes from the line of Frank Takkinen with Light Street Capital. Please go ahead. Great. Thanks for taking the questions. Congrats on the really strong results. Maybe I'll start with a little bit more commentary around Q4. It sounds like you provide a lot of anecdotal comments there about you expect it to continue to be strong. But I think if I picked out two things importantly, it was OUS should be at least as good as Q3, and the procedure volumes should be up also solidly in Q4. So maybe can we talk a little bit more about system placement expectations on capital sales side, and then what do you think we should be thinking about for a healthy procedure volume growth rate for Q4? Thanks. Hey, thanks. Hi, Frank. I appreciate the question, and thank you for the comment on the quarter. So I would expect, per your comment, similar activity from outside U.S. in terms of system shift in the quarter as compared to Q3. It's likely not going to be more, and it should be right in that same area, if you will, given a system either way, one way or another. In terms of procedures, it's interesting because Q4 globally is the highest sort of number of cataract procedures that will be performed globally. On the other hand, there have been a couple of events, given the number of hurricanes and things that have gone on here in the U.S., out of everyone's control, that have certainly affected doctors and anecdotally and even more specifically certain high-volume practices where they basically weren't doing surgery for somewhere between one and three weeks in some cases, and in a couple of cases, one or two people are just getting back. That said, because the Q4 is the highest volume normal procedure quarter on a global basis, these doctors are committed to trying to get all of their backlog done and on track. It's really important at the end of the year for a lot of these patients that have deductibles that have been fulfilled and whatnot to get their surgeries done. So I think we're going to see a strong flurry and finish despite the hurricane activity in the U.S., as well as the fact that we obviously have several substantive holidays towards the end of the year. So I think it's going to be a little lumpy, but I think we're going to go flying into the end of the year with a really strong procedure growth. We're also working to install quite a number of systems as well with goals this quarter, given the backlog and new system activity that we're seeing as well. So I think we'll have good momentum going into the new year. Yeah. And Frank, just to add further color on that, in my comments, I said we expect 10 or 11 systems coming outside of the United States. It's going to be one or the other, but because we fulfilled the backlog over a two-year period, even though it was a short quarter and we're going to have a full quarter outside the United States, you're right in assuming that the level outside the United States is probably right at maybe a system shy of the Q3. And the activity, I said in my remarks, our placement activity in the Q3 was exceptional. I mean, it was just a fabulous quarter for us from a placement perspective, and it would be very difficult for us to increase off of that in the Q4 from a placement perspective just because it was such a phenomenal quarter based on the ex-U.S. activity. We've got the activity, but the thing is the days left to really. Yeah, with the holidays and that type of stuff. The bigger. Exactly. And it's really hard on a procedure volume. We expect it to be strong, but with the hurricane and with the unknown ramp-up time of the lion's share of these sites, including with such a strong placement activity in the Q3, you just don't know when they're going to receive a run rate. But certainly, we think the procedure volume is going to increase. So it's hard having such an exceptional Q3 and then using that as a foundation for the Q4. Got it. That's helpful. Maybe if I could ask pretty much the same exact question for 2025. I know it's maybe a little early to start looking out that far, but hoping you guys can start to dial in how we should be thinking about 2025, both from a placements as well as procedure volume growth perspective. Yeah. I think the way I would think about that, Frank, is we'll give some decent guidance going forward when we wrap up the full year. But as Nick mentioned in his previous comments, this is a game of inches, right? And so we really have to make sure that we have a good idea of when things are going to hit before we really project further than a quarter out. And I don't know if you want to have general comments, Nick, to that. Yeah. I would like to be able to provide you some, as we get to the end of the year and into 2025, I would like to provide you a little more granular guidance as it relates to the procedure, what we expect from a procedure growth, because that's going to be a really important measure. We certainly have goals here to continue to gain market share, and that means that we've got to continue to grow the procedures. And given the number of systems, Tom mentioned, the 40-plus systems having installed since June, you got to think about that on a rolling basis, right? Because it's not like they all get installed on the same day, and then it's a race to get them to their 90 days, and then all of a sudden they're producing procedure numbers. This is rolling. So those 40 systems are being installed at different times, and then they start their training, and by the way, we do all the training at no charge and all the procedures and whatnot to them. And so that whole part of my discussion where I talked about the path to recognizing revenue and procedure revenue, it takes two to three months from the time it's installed to really see it get at a normalized run rate. And that's rolling. So as we get to the end of the year here and I start to see what's happening, I would hope to be able to provide some better guidance as we get into 2025, given this large number of systems that we've grown this year. Got it. That's helpful. And then maybe just for my last one, I was hoping, I think you commented on it a little bit in your prepared remarks, Nick, but just think about the Femto-n aive market a little bit. How should we think about your strategy there? Do you feel like it's time to go after that a little bit more aggressively, or is it still first and foremost take share and then start to look at Femto-n aive from there? It is first and foremost to take share, and I sort of gave in my remarks the sort of order of battle, if you will, which number one are the competitive sites, and part of this has to do with just we have a smaller sales force. We're highly specialized. Our product is very, very specialized, and quite honestly, given where we're moving with robotic cataract laser surgery here, taking someone that heretofore has done nothing and then implementing this in the practice is a far heavier lift for both the customer as well as for LENSAR there, and so the strategy of gaining more momentum and market share through people that already have some familiarity with these technologies and also our high-volume surgeons with high conversion rates is our primary focus because that still is very fertile ground, because with 1,200 lasers in the U.S. alone and 2,000 lasers on a global basis, you have a bolus of lasers there where people have accepted this concept of laser cataract surgery. We're bringing in this robotic, and now you're putting a Ferrari in there, and they can really grow their business. And that's why we've seen 13% of LLS to that and why people that have one to four never used LENSAR are moving to LENSAR. And so that Femto-n aive market that hasn't done it requires a lot more resource, and we want to make sure that we've got this critical mass around us as well because that's very helpful in moving that market. And so that's still a little, it's still a little early for us in that regard. Got it. That's helpful. Thanks for taking the question. Congrats again. I do want to clarify one thing, though. Not to say that we don't have those because we do. We have several accounts that are Femto-n aive, but it's usually where the customer has expressed interest, and they've come forth and are expressing interest rather than our sort of mining for those right now, if that makes any sense. Yep. Perfect. Hey, Frank, one other thing. To understand sort of Nick's comments about the holiday, remember, for us to recognize a system placement in the United States, we have to have a contract, ship it, have it installed, and have the physicians trained, and with the normal Q4, if you don't have all that stuff done by about December 15th or 18th, you effectively lose two, two and a half weeks of the quarter because of holidays, so that's why I said it's important to appreciate that when you're looking at system placements for the Q4. Got it. Thank you. This concludes our Q&A session. I will now turn the call back over to Nick Curtis for the closing remarks. All right. I'd like to thank everybody for joining our call today and certainly for your continued interest in LENSAR. We continue to look forward to good things here, and I look forward to continuing to update you as we make further progress in the exciting remainder of 2024 and as we move into 2025. Thank you for your support. Ladies and gentlemen, that concludes today's call. Thank you all for joining. You may now disconnect.